“…These concepts are illustrated by case reports and vascular images by Banathy et al, Shah and Silver, and Wilkins et al [10][11][12] Cancer therapies can also lead to increased coagulability or damage to the endothelium, further illustrating the multifaceted interaction between cancer, cancer treatment, and CVD. Therefore, indication, timing, and dosing of prophylactic anticoagulation in patients with cancer is an ongoing debate nicely summarized by an editorial by Khorana, 13 as well as a review article by Gomatou et al, 14 the latter discussing the use of prophylactic anticoagulation in the ambulatory setting in patients with lung cancer. The main reason for restraint is an increase in bleeding risk due to close relation or ingrowth of the tumor to blood vessels, a particular challenge in patients with gastric cancer and summarized by Majmudar et al 15 Another exciting and emerging frontier in cardio-oncology is the growing appreciation that common risk factors contribute to co-occurrence of CVD and cancer.…”